Your browser doesn't support javascript.
loading
Effect of danefukang on symptoms and biomarkers in women with endometriosis.
Zhong, Yi-Cun; Zhou, Xiao-Fei; Hou, Chun-Mei; Li, Wei-Ping.
Afiliación
  • Zhong YC; Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Gynecologic Oncology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Zhou XF; Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Gynecologic Oncology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Hou CM; Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Gynecologic Oncology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Li WP; Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Shanghai Key Laboratory of Gynecologic Oncology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: weiping_drlee@sina.com.
Taiwan J Obstet Gynecol ; 58(2): 218-222, 2019 Mar.
Article en En | MEDLINE | ID: mdl-30910142
OBJECTIVE: The purpose of this study was to observe the efficacy of Danefukang (DEFK) soft extract for the treatment of symptoms associated with endometriosis, and its effect on quality of life, the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) scores, and on levels of carbohydrate antigen (CA)-125, tumor necrosis factor (TNF)-α, and interleukin (IL)-6. MATERIALS AND METHODS: A total of 174 patients with endometriosis treated from January 2010 to December 2013 were randomly divided into a control group treated with mifepristone (n = 87) or DEFK (n = 87). Both groups were treated for 3 months. Symptoms, quality of life, SAS, SD scores, and levels of CA-125, TNF-α, and IL-6 were evaluated before and after treatment. RESULTS: The effectiveness rate was 93.10% in the DEFK group and 81.61% in the mifepristone control group (χ2 = 4.215, P < 0.05). Treatment with DEFK resulted in a greater improvement in quality of life, SDS, and SAS scores compared with mifepristone (all, P < 0.05). DEFK treatment also resulted in a greater decrease of CA-125, TNF-α, and IL-6 levels compared with mifepristone (all, P < 0.05). CONCLUSION: Based on the current results - improved symptoms, attenuated depression and anxiety, and reduced the levels of pro-inflammatory cytokines and CA-125 -treatment with DEFK is a meaningful option for patients with endometriosis. DEFK fills an unmet need in the pharmacologic treatment of endometriosis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Medicamentos Herbarios Chinos / Endometriosis Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: Taiwan J Obstet Gynecol Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Medicamentos Herbarios Chinos / Endometriosis Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: Taiwan J Obstet Gynecol Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: China